These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17893570)

  • 1. Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
    Buti S; Brighenti M; Bongiovanni C; Buzio C; Chiesa MD; Alberici F; Passalacqua R
    J Immunother; 2007 Oct; 30(7):780-6. PubMed ID: 17893570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
    Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
    Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
    Buti S; Lazzarelli S; Chiesa MD; Simonelli C; Re GL; Lheshi A; Simon S; Mattioli R; Caminiti C; Mazza G; Donini M; Passalacqua R;
    J Immunother; 2010 Sep; 33(7):735-41. PubMed ID: 20664353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
    Ryan CW; Vogelzang NJ; Stadler WM
    Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
    Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P
    World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
    J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
    Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
    Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis.
    Roigas J; Deger S; Taymoorian K; Wille AH; Johannsen M; Türk I; Schnorr D; Loening SA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):157-63. PubMed ID: 12804041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
    Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
    Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
    Rini BI; Vogelzang NJ; Dumas MC; Wade JL; Taber DA; Stadler WM
    J Clin Oncol; 2000 Jun; 18(12):2419-26. PubMed ID: 10856102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
    Conter HJ; Lim ZD; Ng CS; Millikan RE; Tannir NM
    Clin Genitourin Cancer; 2013 Sep; 11(3):370-3. PubMed ID: 23665133
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
    George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
    Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
    Hofmockel G; Langer W; Theiss M; Gruss A; Frohmüller HG
    J Urol; 1996 Jul; 156(1):18-21. PubMed ID: 8648791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.
    Roubaud G; Gross-Goupil M; Wallerand H; de Clermont H; Dilhuydy MS; Ravaud A
    Oncology; 2011; 80(3-4):214-8. PubMed ID: 21720184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
    Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.